宜明昂科-B(01541.HK) 公布,连同Instil Bio, Inc.宣布IMM2510/AXN-2510的临床最新情况及未来计划。预计将于今年第三季度在内地完成成IMM2510/AXN-2510联合化疗治疗一线NSCLC患者的2期试验的约60名患者入组,而2期试验的初步安全性及有效性结果预计将于今年下半年公布。3期试验预计明年年中在内地启动,目前尚待与监管部门商讨。IMM2510/AXN-...
Source Link宜明昂科-B(01541.HK) 公布,连同Instil Bio, Inc.宣布IMM2510/AXN-2510的临床最新情况及未来计划。预计将于今年第三季度在内地完成成IMM2510/AXN-2510联合化疗治疗一线NSCLC患者的2期试验的约60名患者入组,而2期试验的初步安全性及有效性结果预计将于今年下半年公布。3期试验预计明年年中在内地启动,目前尚待与监管部门商讨。IMM2510/AXN-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.